Experimental hepatitis b drug shows promise in early trial
NCT ID NCT02604199
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tested an experimental drug called ARC-520 in 58 people with chronic hepatitis B who were already taking standard antivirals. The goal was to see if ARC-520 could further lower hepatitis B surface antigen levels, a marker of the virus. The study was terminated early, so final results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ARC-520 (an experimental RNA interference drug)
What this could lead to
If successful, ARC-520 could help control hepatitis B more effectively by reducing viral proteins, potentially lowering the risk of liver damage.
What could go wrong
This was an early Phase 2 trial that was terminated, so results are limited. The drug may not work as hoped, and side effects are possible. Patients still need lifelong antiviral medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Hong Kong, 999077, China
-
Research Site 10
Leipzig, 04103, Germany
-
Research Site 11
Frankfurt, 60590, Germany
-
Research Site 12
Yangsan-si Gyeongnam, 626-770, South Korea
-
Research Site 13
Busan, 602-739, South Korea
-
Research Site 14
Seoul, 110-744, South Korea
-
Research Site 15
Incheon, 405-760, South Korea
-
Research Site 16
Seoul, 120-752, South Korea
-
Research Site 2
Hong Kong, China
-
Research Site 3
Tübingen, 72076, Germany
-
Research Site 4
Leipzig, 4103, Germany
-
Research Site 5
München, 81377, Germany
-
Research Site 6
Ulm, 89081, Germany
-
Research Site 7
Würzburg, 97080, Germany
-
Research Site 8
Hanover, 30625, Germany
-
Research Site 9
Hamburg, 20099, Germany